TERM ID="NYU_TERM_1" STRING="CD5 expression" FREQUENCY=1 START=202 END=216 LEMMA="CD5 EXPRESSION" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_2" STRING="CHOP" FREQUENCY=1 START=552 END=556 LEMMA="CHOP" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_3" STRING="CHOP-R" FREQUENCY=1 START=630 END=636 LEMMA="CHOP-R" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_4" STRING="Clinical roundtable monograph" FREQUENCY=1 START=0 END=29 LEMMA="CLINICAL ROUNDTABLE MONOGRAPH" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_5" STRING="Hematology" FREQUENCY=1 START=957 END=967 LEMMA="HEMATOLOGY" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_6" STRING="Louisiana" FREQUENCY=1 START=1045 END=1054 LEMMA="LOUISIANA" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_7" STRING="MCL" FREQUENCY=1 START=138 END=141 LEMMA="MCL" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_8" STRING="Mantle cell lymphoma" FREQUENCY=1 START=116 END=136 LEMMA="MANTLE CELL LYMPHOMA" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_9" STRING="Recent advances" FREQUENCY=1 START=31 END=46 LEMMA="RECENT ADVANCE" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_10" STRING="Traditional treatments" FREQUENCY=1 START=409 END=431 LEMMA="TRADITIONAL TREATMENT" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_11" STRING="addition" FREQUENCY=1 START=563 END=571 LEMMA="ADDITION" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_12" STRING="addition of the immunotherapeutic agent rituximab" FREQUENCY=1 START=563 END=612 LEMMA="IMMUNOTHERAPEUTIC AGENT RITUXIMAB ADDITION" LEMMA_FREQUENCY=1 HEAD_TERM="addition" HEAD_LEMMA="ADDITION"
TERM ID="NYU_TERM_13" STRING="agent bendamustine" FREQUENCY=1 START=1301 END=1319 LEMMA="AGENT BENDAMUSTINE" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_14" STRING="clinical roundtable monograph" FREQUENCY=1 START=1064 END=1093 LEMMA="CLINICAL ROUNDTABLE MONOGRAPH" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_15" STRING="combinations" FREQUENCY=1 START=816 END=828 LEMMA="COMBINATION" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_16" STRING="conventional chemotherapy agents" FREQUENCY=1 START=448 END=480 LEMMA="CONVENTIONAL CHEMOTHERAPY AGENT" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_17" STRING="cyclin D1 gene" FREQUENCY=1 START=296 END=310 LEMMA="CYCLIN D1 GENE" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_18" STRING="cyclophosphamide, doxorubicin, vincristine, and prednisone" FREQUENCY=1 START=492 END=550 LEMMA="CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE, AND PREDNISONE" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_19" STRING="cytogenetic translocation" FREQUENCY=1 START=232 END=257 LEMMA="CYTOGENETIC TRANSLOCATION" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_20" STRING="discussion Mantle cell lymphoma" FREQUENCY=1 START=105 END=136 LEMMA="DISCUSSION MANTLE CELL LYMPHOMA" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_21" STRING="doxorubicin" FREQUENCY=1 START=510 END=521 LEMMA="DOXORUBICIN" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_22" STRING="drug classes" FREQUENCY=1 START=1161 END=1173 LEMMA="DRUG CLASS" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_23" STRING="immunomodulatory agents" FREQUENCY=1 START=1325 END=1348 LEMMA="IMMUNOMODULATORY AGENT" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_24" STRING="immunotherapeutic agent rituximab" FREQUENCY=1 START=579 END=612 LEMMA="IMMUNOTHERAPEUTIC AGENT RITUXIMAB" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_25" STRING="including cyclophosphamide" FREQUENCY=1 START=482 END=508 LEMMA="INCLUDING CYCLOPHOSPHAMIDE" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_26" STRING="mTOR" FREQUENCY=1 START=1272 END=1276 LEMMA="MAMMALIAN TARGET OF RAPAMYCIN" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_27" STRING="mammalian target of rapamycin" FREQUENCY=1 START=1241 END=1270 LEMMA="MAMMALIAN TARGET OF RAPAMYCIN" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_28" STRING="mantle cell lymphoma" FREQUENCY=1 START=67 END=87 LEMMA="MANTLE CELL LYMPHOMA" LEMMA_FREQUENCY=2
TERM ID="NYU_TERM_29" STRING="non-Hodgkin lymphoma" FREQUENCY=1 START=164 END=184 LEMMA="NON-HODGKIN LYMPHOMA" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_30" STRING="overexpression" FREQUENCY=1 START=274 END=288 LEMMA="OVEREXPRESSION" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_31" STRING="overexpression of the cyclin D1 gene" FREQUENCY=1 START=274 END=310 LEMMA="CYCLIN D1 GENE OVEREXPRESSION" LEMMA_FREQUENCY=1 HEAD_TERM="overexpression" HEAD_LEMMA="OVEREXPRESSION"
TERM ID="NYU_TERM_32" STRING="post-ASH" FREQUENCY=1 START=91 END=99 LEMMA="POST-ASH" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_33" STRING="prednisone" FREQUENCY=1 START=540 END=550 LEMMA="PREDNISONE" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_34" STRING="proteasome inhibitors" FREQUENCY=1 START=1192 END=1213 LEMMA="PROTEASOME INHIBITOR" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_35" STRING="protein mammalian target" FREQUENCY=1 START=1233 END=1257 LEMMA="PROTEIN MAMMALIAN TARGET" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_36" STRING="protein mammalian target of rapamycin" FREQUENCY=1 START=1233 END=1270 LEMMA="RAPAMYCIN PROTEIN MAMMALIAN TARGET" LEMMA_FREQUENCY=1 HEAD_TERM="protein mammalian target" HEAD_LEMMA="PROTEIN MAMMALIAN TARGET"
TERM ID="NYU_TERM_37" STRING="rapamycin" FREQUENCY=1 START=1261 END=1270 LEMMA="RAPAMYCIN" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_38" STRING="subtype" FREQUENCY=1 START=153 END=160 LEMMA="SUBTYPE" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_39" STRING="subtype of non-Hodgkin lymphoma" FREQUENCY=1 START=153 END=184 LEMMA="NON-HODGKIN LYMPHOMA SUBTYPE" LEMMA_FREQUENCY=1 HEAD_TERM="subtype" HEAD_LEMMA="SUBTYPE"
TERM ID="NYU_TERM_40" STRING="t(11" FREQUENCY=1 START=223 END=227 LEMMA="T(11" LEMMA_FREQUENCY=1
TERM ID="NYU_TERM_41" STRING="vincristine" FREQUENCY=1 START=523 END=534 LEMMA="VINCRISTINE" LEMMA_FREQUENCY=1
